SSH2 (slingshot protein phosphatase 2) is a serine phosphatase that regulates actin cytoskeleton dynamics by dephosphorylating and activating cofilin, an actin-depolymerizing factor 1. This function is essential for controlling F-actin dynamics during cellular processes requiring cytoskeletal remodeling. SSH2 operates within the GPCR-mediated PLCβγ/PKCβ/PKD signaling pathway to coordinate actin polymerization and depolymerization during neutrophil chemotaxis 1. Dysregulation of SSH2 has significant disease relevance. In Birt-Hogg-Dubé (BHD) syndrome, SSH2 knockdown selectively triggers apoptosis in FLCN-deficient cells through cell cycle arrest and increased caspase 3/7 activation, identifying SSH2 as a potential synthetic-lethal therapeutic target for BHD-associated renal cell carcinoma 2. SSH2 has also been implicated as a novel ALK fusion partner in lung adenocarcinoma cases sensitive to crizotinib therapy 3. Mendelian randomization studies identify SSH2 expression decreases in epilepsy risk and increases in Alzheimer's disease risk, with elevated expression in microglia associated with actin regulation 45. SSH2 expression also contributes to predictive models for bloodstream infections in pediatric burn patients 6. These diverse roles suggest SSH2 functions as both a disease-relevant biomarker and therapeutic target across multiple pathological conditions.